Drugs / Vaccination
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01042366 | Oct 2002 → Nov 2014 | metastatic melanoma | John Kirkwood | Terminated | No outcome recorded Stop: Enrollment |
| Phase 31 trial | ||||||
| Phase 3 | NCT04814446 | Jun 2022 → Jun 2025 | common wart | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05356312 | — | malignant glioma | Zentrum fur Humangenetik Tuebingen | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaccination | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04814446 ↗ |
| Modality | Vaccine | “experimental tumor vaccine” NCT01042366 ↗ |
| Route | Other | “intra/peri-lymph nodal administrations” NCT01042366 ↗ |